Featured Clinical review September 4, 2026 Gene Therapy for Cholesterol: VERVE-102, Heart-2 and HEART-3 PCSK9 base editing with VERVE-102 is not an approved therapy. Heart-2 phase 1b data show dose-dependent LDL lowering, while the HEART-3 phase 2 trial has not yet started recruiting. 04 Sep Est. reading time: 8 min Read article